All In Biotech

Drug Trial Radar · NCT03992430

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients With Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Jul 13, 2020

Primary completion

Sep 7, 2026

Study completion Sep 7, 2026

Sponsor

Lead sponsor
Sarepta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 200 mg/kg) of eteplirsen compared with that of the 30 mg/kg dose of eteplirsen, in approximately 144 participants with genetically confirmed deletion mutations amenable to treatment by skipping exon 51.

Conditions

  • Muscular Dystrophy, Duchenne

Interventions

  • EteplirsenDrug

    Solution for intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of Adverse Events (AEs)Time frame: Up to Week 148
  2. Part 2: Change From Baseline at Week 144 in the NSAA Total Score (for Final Analysis)Time frame: Baseline, Week 144
  3. Part 2: Change from Baseline at Week 72 or Week 96 in NSAA Total Score (for Conditional Efficacy Interim Analysis)Time frame: Baseline, Week 72 or Week 96

Locations

59 sites in 26 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Florida

    Gainesville, Florida

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • Hospital Universitario San Ignacio

    Bogotá, Colombia

  • Instituto Neurologico de Colombia (INDEC)

    Medellín, Colombia

  • Hospital Pablo Tobón Uribe

    Medellín, Colombia

  • Brno Klinika detske neurologie

    Brno, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Rigshospitalet Copenhagen University Hospital

    Copenhagen, Denmark

  • Hopital Femme Mere Enfant

    Bron, France

  • Hopital Armand Trousseau

    Paris, France

  • CHRU de Strasbourg

    Strasbourg, France

  • Charité Universitätsmedizin Berlin CVK

    Berlin, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • IASO Children's Hospital

    Marousi, Attica, Greece

  • Semmelweis Egyetem Genomikai Medicina és Ritka Betegsegek Intezete

    Budapest, Hungary

  • Royal Institute of Child Neurosciences

    Ahmedabad, India

  • Aster RV Hospital

    Bengaluru, India

  • Nizam's Institute of Medical Sciences

    Hyderabad, India

  • Jaicare Hospital (A Unit of Sarvee Integra Pvt Ltd.)

    Madurai, India

  • All India Institute of Medical Sciences

    New Delhi, India

  • Sir Ganga Ram Hospital

    New Delhi, India

  • Deenanath Mangeshkar Hospital & Research Centre

    Pune, India

  • Christian Medical College

    Vellore, India

  • Children's Health Ireland (CHI) at Temple Street

    Dublin, Ireland

  • IRCCS Instituto Gianna Gaslini

    Genova, Italy

  • Fondazione Policlinico Universitario A. Gemelli- IRCCS

    Rome, Italy

  • The Specialty Hospital (TSH)/Advanced Clinical Center

    Amman, Jordan

  • Istiklal Hosptial (IST)

    Amman, Jordan

  • Irbid Specialty Hospital

    Irbid, Jordan

  • Pharmaceutical Research Center/Jordan University of Science and Technology

    Irbid, Jordan

  • Instituto de Investigaciones Clinicas para la Salud A.C

    Durango, Mexico

  • Neurociencias Estudios Clínicos S.C.

    Culiacán, Sinaloa, Mexico

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Radboud University Nijmegen Medical Centre

    Nijmegen, Netherlands

  • New Zealand Clinical Research - Auckland

    Auckland, New Zealand

  • Oslo Universitetssykehus HF Rikshospitalet

    Oslo, Norway

  • Children's Department and Department for Children's Habilitation at Stavanger University Hospital

    Stavanger, Norway

  • Klinika Neurologii Rozwojowej

    Gdansk, Pomeranian Voivodeship, Poland

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.